CellNetix Chief Scientific Officer, Dr. Danbin Xu, presented a poster titled “A Pathology Group Experience with Targeted Next Generation Sequencing (NGS) for Non-Small-Cell-Lung Cancer (NSCLC)” at the Association for Molecular Pathology (AMP) 2019 Annual Meeting on November 7-9 in Baltimore, MD. The poster was authored by Dr. Danbin Xu and Dr. Sean Keenan, et. al. The study examined 465 NSCLC patients utilizing a CellNetix customized NGS_Lung panel that evaluated for small mutations and copy number changes in 13 genes (ALK, ARAF, BRAF, EGFR, ERBB2, KRAS, MAP2K1, MET, MTOR, NRAS, RET, ROS1, TP53), plus RET translocations.
The study found 23% were positive for at least one actionable mutation (KRAS was not included). Among them, 7.3% of the patients carried actionable mutations in MET, ERBB2, RET, and ARAF, which would not have been identified if only EGFR or BRAF was analyzed as a single gene. Overall this panel compares favorably to larger NGS panels if Tumor Mutation Burden is not a consideration.
To learn more about this panel and how it can be ordered, visit the Lung Cancer NGS Panel page.